1. Home
  2. ALT vs ATEX Comparison

ALT vs ATEX Comparison

Compare ALT & ATEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALT
  • ATEX
  • Stock Information
  • Founded
  • ALT 1997
  • ATEX 1997
  • Country
  • ALT United States
  • ATEX United States
  • Employees
  • ALT N/A
  • ATEX N/A
  • Industry
  • ALT Biotechnology: Pharmaceutical Preparations
  • ATEX Telecommunications Equipment
  • Sector
  • ALT Health Care
  • ATEX Telecommunications
  • Exchange
  • ALT Nasdaq
  • ATEX Nasdaq
  • Market Cap
  • ALT 348.6M
  • ATEX 381.9M
  • IPO Year
  • ALT N/A
  • ATEX N/A
  • Fundamental
  • Price
  • ALT $4.05
  • ATEX $20.22
  • Analyst Decision
  • ALT Strong Buy
  • ATEX Buy
  • Analyst Count
  • ALT 7
  • ATEX 2
  • Target Price
  • ALT $16.50
  • ATEX $58.50
  • AVG Volume (30 Days)
  • ALT 2.8M
  • ATEX 171.6K
  • Earning Date
  • ALT 11-06-2025
  • ATEX 11-12-2025
  • Dividend Yield
  • ALT N/A
  • ATEX N/A
  • EPS Growth
  • ALT N/A
  • ATEX N/A
  • EPS
  • ALT N/A
  • ATEX 1.58
  • Revenue
  • ALT $20,000.00
  • ATEX $5,924,000.00
  • Revenue This Year
  • ALT N/A
  • ATEX N/A
  • Revenue Next Year
  • ALT N/A
  • ATEX $5.18
  • P/E Ratio
  • ALT N/A
  • ATEX $12.82
  • Revenue Growth
  • ALT N/A
  • ATEX 15.97
  • 52 Week Low
  • ALT $2.90
  • ATEX $19.09
  • 52 Week High
  • ALT $11.16
  • ATEX $42.91
  • Technical
  • Relative Strength Index (RSI)
  • ALT 54.55
  • ATEX 45.46
  • Support Level
  • ALT $3.93
  • ATEX $19.09
  • Resistance Level
  • ALT $4.25
  • ATEX $20.40
  • Average True Range (ATR)
  • ALT 0.18
  • ATEX 0.74
  • MACD
  • ALT 0.00
  • ATEX -0.04
  • Stochastic Oscillator
  • ALT 56.99
  • ATEX 41.48

About ALT Altimmune Inc.

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

About ATEX Anterix Inc.

Anterix Inc is a United States-based company engaged in delivering broadband needed to modernize infrastructure for energy, transportation, logistics, and other industries. The company offers Private LTE for utilities which help to automate processes, monitor environmental conditions, enable artificial intelligence, and drive productivity.

Share on Social Networks: